<?xml version="1.0" encoding="UTF-8"?>
<p>Pulse oximetry, respiratory frequency, and chest X-ray films determine the clinical management of patients and the need for hospitalization. Multiple therapeutic approaches have been proposed and are being studied in clinical trials, including antiviral agents and hydroxychloroquine [
 <xref ref-type="bibr" rid="CR12">12</xref>–
 <xref ref-type="bibr" rid="CR14">14</xref>]; widespread uptake of the latter has resulted in supply restrictions for dermatologic patients with indications for antimalarials [
 <xref ref-type="bibr" rid="CR15">15</xref>]. Corticosteroids are generally contraindicated in the treatment of COVID-19 [
 <xref ref-type="bibr" rid="CR16">16</xref>], but the underlying cytokine storm has provided the basis for therapeutic attempts with selective immunosuppressants such as TNFα inhibitors, Janus kinase inhibitors, anti-IL-1 agents, and anti-IL-6 drugs such as tocilizumab [
 <xref ref-type="bibr" rid="CR17">17</xref>, 
 <xref ref-type="bibr" rid="CR18">18</xref>].
</p>
